BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17634423)

  • 1. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.
    Cheng CJ; Ye XC; Vakar-Lopez F; Kim J; Tu SM; Chen DT; Navone NM; Yu-Lee LY; Lin SH; Hu MC
    Mol Cancer Res; 2007 Jul; 5(7):675-84. PubMed ID: 17634423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and nuclear localization of ErbB3 in prostate cancer.
    Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
    Awasthi S; Ezelle H; Hassel BA; Hamburger AW
    Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation.
    Daniels G; Zhang X; Zhong X; Santiago L; Wang LH; Wu X; Zhang JY; Liang F; Li X; Neubert TA; Steinke L; Shen Y; Basch R; Schneider R; Levy DE; Lee P
    Oncotarget; 2016 Jun; 7(26):39556-39571. PubMed ID: 27127173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
    Lee YC; Cheng CJ; Huang M; Bilen MA; Ye X; Navone NM; Chu K; Kao HH; Yu-Lee LY; Wang Z; Lin SH
    J Pathol; 2010 May; 221(1):68-76. PubMed ID: 20191612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells.
    Koumakpayi IH; Le Page C; Delvoye N; Saad F; Mes-Masson AM
    Mol Carcinog; 2011 Nov; 50(11):901-12. PubMed ID: 21438025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
    Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
    Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer.
    Sampson N; Ruiz C; Zenzmaier C; Bubendorf L; Berger P
    Am J Pathol; 2012 Oct; 181(4):1443-54. PubMed ID: 22885105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
    Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.
    Meng TC; Lee MS; Lin MF
    Oncogene; 2000 May; 19(22):2664-77. PubMed ID: 10851066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors.
    Lescarbeau RM; Seib FP; Prewitz M; Werner C; Kaplan DL
    PLoS One; 2012; 7(8):e40372. PubMed ID: 22870197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.